# Chinese PLA General Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/chinese-pla-general-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 33.9 |
| Citations | 2,908,962 |
| City | Beijing |
| Country | CN |
| Description | Chinese PLA General Hospital is a research organisation in Beijing, CN. OpenAlex records 54,413 works and 2,908,962 citations for it. 19,215 researchers list it as their most recent affiliation. |
| Homepage | http://www.301hospital.com.cn/en2012/web/Introduction.html |
| OpenAlex ID | https://openalex.org/I2802939634 |
| Region | Beijing |
| Researchers | 19,215 |
| ROR ID | https://ror.org/04gw3ra78 |
| Type | healthcare |
| Works | 54,413 |

## University papers

Showing 12 of 88.

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas](https://scholariq.org/papers/covid-19-immune-features-revealed-by-a-large-scale-single-cell-transcriptome/)
- [A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity](https://scholariq.org/papers/a-vaccine-targeting-the-rbd-of-the-s-protein-of-sars-cov-2-induces-protective/)
- [Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study](https://scholariq.org/papers/camrelizumab-versus-investigator-s-choice-of-chemotherapy-as-second-line-therapy/)
- [Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis](https://scholariq.org/papers/diagnostic-accuracy-of-angiography-based-quantitative-flow-ratio-measurements/)
- [Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer](https://scholariq.org/papers/tarlatamab-for-patients-with-previously-treated-small-cell-lung-cancer/)
- [Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial](https://scholariq.org/papers/camrelizumab-plus-carboplatin-and-pemetrexed-versus-chemotherapy-alone-in/)
- [γδ T cells: origin and fate, subsets, diseases and immunotherapy](https://scholariq.org/papers/t-cells-origin-and-fate-subsets-diseases-and-immunotherapy/)
- [Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients](https://scholariq.org/papers/functional-impairment-in-circulating-and-intrahepatic-nk-cells-and-relative/)
- [Empagliflozin after Acute Myocardial Infarction](https://scholariq.org/papers/empagliflozin-after-acute-myocardial-infarction/)
- [Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update)](https://scholariq.org/papers/guideline-of-prevention-and-treatment-for-chronic-hepatitis-b-2015-update/)
- [The antifungal effect of silver nanoparticles on Trichosporon asahii](https://scholariq.org/papers/the-antifungal-effect-of-silver-nanoparticles-on-trichosporon-asahii/)

## University researchers

- [Yundai Chen](https://scholariq.org/researchers/yundai-chen/)
- [Jianzheng Zhang](https://scholariq.org/researchers/jianzheng-zhang/)
- [Shuwei Duan](https://scholariq.org/researchers/shuwei-duan/)
- [Wei Zhang](https://scholariq.org/researchers/wei-zhang-4/)
- [Zhikuan Xia](https://scholariq.org/researchers/zhikuan-xia/)
- [Chao Wang](https://scholariq.org/researchers/chao-wang-2/)
- [Huayong Zheng](https://scholariq.org/researchers/huayong-zheng/)
- [Qingjun Wang](https://scholariq.org/researchers/qingjun-wang/)
- [P Chen](https://scholariq.org/researchers/p-chen/)
- [Z X Duan](https://scholariq.org/researchers/z-x-duan/)
- [Zhe Feng](https://scholariq.org/researchers/zhe-feng/)

## University top topics

Showing 8 of 25.

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer-related molecular mechanisms research](https://scholariq.org/topics/cancer-related-molecular-mechanisms-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [MicroRNA in disease regulation](https://scholariq.org/topics/microrna-in-disease-regulation/)
- [Ferroptosis and cancer prognosis](https://scholariq.org/topics/ferroptosis-and-cancer-prognosis/)
- [Mesenchymal stem cell research](https://scholariq.org/topics/mesenchymal-stem-cell-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.